Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.
Psychopharmacol Bull. 2022 Feb 25;52(1):57-60.
Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness. Clozapine remains a viable option, albeit off-label, but is clearly underutilized in this population. Use is typically fraught with panoply of drastic side effects. Here, authors report on an adolescent case with schizophrenia that responded ultimately to clozapine. Add-on viloxazine was advantageous spanning different symptom domains, mitigating metabolic parameters and addressing clozapine-sialorrhea. This might open new venues for such complicated, yet commonplace, clinical scenarios.
早发性精神分裂症预后差且对治疗无反应，恶名昭著。氯氮平仍然是一种可行的选择，尽管是超适应证使用，但在该人群中的使用显然不足。使用氯氮平通常伴随着各种各样的严重副作用。在这里，作者报告了一例对氯氮平最终有反应的青少年精神分裂症病例。添加文拉法辛在不同的症状领域都有优势，可减轻代谢参数并解决氯氮平流涎问题。这可能为这种复杂但常见的临床情况开辟新的途径。
